Mechanical thrombectomy is cost-effective versus medical management alone around Europe in patients with low ASPECTS.

MT is efficient versus MM alone for patients with low ASPECTS in eight countries across Europe. Patients with a large ischemic core could be treated with MT because it is both clinically beneficial and economically sustainable.